Lyra Therapeutics Inc (NASDAQ:LYRA) has a beta value of 0.04 and has seen 0.86 million shares traded in the recent trading session. The LYRA stock price is -5141.67% off its 52-week high price of $6.29 and 0.0% above the 52-week low of $0.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.71 million shares traded. The 3-month trading volume is 1.01 million shares.
The consensus among analysts is that Lyra Therapeutics Inc (LYRA) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Sporting -0.96% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the LYRA stock price touched $0.12 or saw a rise of 25.0%. Year-to-date, Lyra Therapeutics Inc shares have moved -42.37%, while the 5-day performance has seen it change -23.70%. Over the past 30 days, the shares of Lyra Therapeutics Inc (NASDAQ:LYRA) have changed -34.64%. Short interest in the company has seen 2.4 million shares shorted with days to cover at 2.53.
Wall Street analysts have a consensus price target for the stock at $0.5, which means that the shares’ value could jump 76.0% from the levels at last check today. The projected low price target is $0.5 while the price target rests at a high of $0.5. In that case, then, we find that the latest price level in today’s session is -316.67% off the targeted high while a plunge would see the stock gain -316.67% from the levels at last check today.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
The company’s shares have lost -53.72% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -43.92%.
3 analysts offering their estimates for the company have set an average revenue estimate of 160k for the current quarter. 3 have an estimated revenue figure of 161.33k for the next ending quarter. Year-ago sales stood 532k and 598k respectively for this quarter and the next, and analysts expect sales will shrink by -69.92% for the current quarter and -43.92% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.22% over the past 5 years. Earnings growth for 2025 is a modest 42.42% while over the next 5 years, the company’s earnings are expected to increase by 21.95%.
LYRA Dividends
Lyra Therapeutics Inc is expected to release its next earnings report on 2025-Mar-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Insiders own 0.42% of the company shares, while shares held by institutions stand at 50.86% with a share float percentage of 51.07%. Investors are also buoyed by the number of investors in a company, with Lyra Therapeutics Inc having a total of 76.0 institutions that hold shares in the company. The top two institutional holders are PERCEPTIVE ADVISORS LLC with over 12.76 million shares worth more than $3.53 million. As of 2024-06-30, PERCEPTIVE ADVISORS LLC held 19.4892% of shares outstanding.
The other major institutional holder is CITADEL ADVISORS LLC, with the holding of over 4.77 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.32 million and represent 7.2912% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. As of Feb 28, 2025, the former fund manager holds about 3.52% shares in the company for having 2.32 shares of worth $0.28 million while later fund manager owns 992.54 shares of worth $0.12 million as of Dec 31, 2024, which makes it owner of about 1.51% of company’s outstanding stock.
